Surface Plasmon Resonance Immunosensor with Antibody-Functionalized Magnetoplasmonic Nanoparticles for Ultrasensitive Quantiﬁcation of the CD5 Biomarker

Asta Kausaite-Minkstimiene,* Anton Popov, and Almira Ramanaviciene*

ABSTRACT: A surface plasmon resonance (SPR) immunosensor signal amplification strategy based on antibody-functionalized gold-coated magnetic nanoparticles (mAuNPs) was developed for ultrasensitive and quantitative detection of the CD5 biomarker using an indirect sandwich immunoassay format. The gold surface of the SPR sensor disk and mAuNPs was modiﬁed with a self-assembled monolayer of 11-mercaptoundecanoic acid (11-MUA), and the coupling method using N-(3-(dimethylamino)propyl)-N'-ethyl-carbodiimide hydrochloride and N-hydroxysuccinimide was used to immobilize capture antibodies against human CD5 (anti-CD52A) and detection antibodies against human CD5 (anti-CD52B), respectively. The mAuNPs and anti-CD52B conjugates (mAuNPs−anti-CD52B) were separated by an external magnetic ﬁeld and used to amplify the SPR signal after the formation of the anti-CD52A/CD5 immune complex on the SPR sensor disk. Compared to the direct CD5 detection with a limit of detection (LOD) of 1.04 nM and a limit of quantiﬁcation (LOQ) of 3.47 nM, the proposed sandwich immunoassay utilizing mAuNPs−anti-CD52B signiﬁcantly improved the LOD up to 8.31 fM and the LOQ up to 27.70 fM. In addition, it showed satisfactory performance in human blood serum (recovery of 1.04 pM CD5 was 109.62%). These results suggest that the proposed signal ampliﬁcation strategy has superior properties and oﬀers the potential to signiﬁcantly increase the sensitivity of the analysis.

KEYWORDS: surface plasmon resonance, immunosensor, CD5, gold-coated magnetic nanoparticles, signal enhancement

1. INTRODUCTION

According to the International Agency for Research on Cancer, oncological diseases are the largest cause of premature death in the world. Nearly 20 million new cases were diagnosed in 2020, with nearly 10 million deaths.¹ In order to reduce mortality and the cost of treatment and rehabilitation of oncological patients, reliable methods are needed to diagnose the disease at an early stage and to select the most optimal treatment method for each patient. The earlier cancer is diagnosed, the more likely it is that treatment will be effective and patients will have a better quality of life than those diagnosed later.² Thus, the quantiﬁcation of cancer biomarkers is very important, and the development of new methods with high sensitivity and precision, which would enable the detection of oncological disease at an early stage, is still needed. In recent years, among various biochemical methods, surface plasmon resonance (SPR) immunosensors have received great interest and have become one of the most promising methods to detect and quantify a variety of important biomarkers, including biomarkers for cancer.³ An important advantage of SPR immunosensors compared to traditional antibody–antigen interaction assay methods is that they are able to provide real-time detection of analytes without any labels. SPR immunosensors are very sensitive, allowing for the detection of extremely low concentrations in a relatively small sample volume. Furthermore, they are able to detect and quantify analytes in solutions with high levels of foreign substances, eliminating the need for a time-consuming sample preparation procedure. The duration of an analysis with the SPR immunosensor often does not exceed a few or several minutes, and multiple analysis can be performed after proper regeneration of the SPR sensor surface.⁴

The suitability of SPR immunosensors for the detection of cancer biomarkers has been demonstrated both in the direct label-free detection format and in various indirect detection formats. Mohseni et al. fabricated a label-free SPR immunosensor for the detection of human matrix metalloproteinase-9 in saliva samples.⁵ The developed immunosen-
sor had a linear range of 10–200 ng/mL with a limit of detection (LOD) of 8 pg/mL, which was lower than most of the other techniques proposed previously. Jena et al. proposed an SPR immunosensor for label-free detection of a Baculoviral inhibitor of the apoptosis repeat containing-5 protein biomarker in serum as low as 6.25 pg/mL. Although SPR immunosensors can quantify analytes without any labels, low-molecular-weight analytes or analytes at very low concentrations in samples are difficult to detect in direct detection format. In the above-mentioned cases, the interaction between the immobilized ligand and the analyte causes only a small change in the refractive index of the medium resulting in a very small analytical signal. Therefore, the direct format is often not suitable for the detection of nanomolar or lower concentrations. In recent years, this problem has been largely addressed through the use of a variety of nanomaterials. Due to their high mass, these materials provide a much greater change in refractive index, enhance the analytical signal, and increase the sensitivity of the SPR immunosensor. For example, Wang et al. used conjugates of detection antibodies and quantum dots to amplify the analytical signal in a sandwich immunoassay format. The developed immunosensor made it possible to quantify α-fetoprotein (AFP), carcinoembryonic antigen (CEA), and the cytokeratin 21-1 fragment in clinical samples over a wide concentration range from 1 to 1000 ng/mL with a LOD of 0.1 ng/mL. Ermini et al. proposed an SPR immunosensor for the detection of CEA in blood plasma, the analytical signal of which was amplified using detection antibodies conjugated to gold nanoparticles (AuNPs). Eletxigerra et al. used streptavidin decorated AuNPs and a dual sandwich amplification strategy to develop an SPR immunosensor for the breast cancer biomarker Epidermal Growth Receptor Factor 2 detection in human serum samples and raw cancer cell lysates. The LOD for 50% diluted human serum samples was found to be 180 pg/mL. This concentration is 83 times lower than the clinical limit. Krishnan et al. used conjugates of detection antibodies and superparamagnetic particles to detect prostate specific antigen in serum with an ultralow LOD of 10 fg/mL.

Among various nanomaterials, magnetic core–shell nanoparticles consisting of the magnetic nanoparticle and a gold shell (mAuNPs) are highly attractive due to their special properties. mAuNPs not only provide stable binding sites for the immobilization of the biomaterial on their surfaces but also facilitate the separation and concentration of the resulting bioconjugates. In addition, mAuNPs increase the SPR signal not only due to high mass but also due to electromagnetic enhancement in the evanescent field at the SPR sensor surface caused by the localized surface plasmons excited in the nanoparticles. However, only a limited number of studies have used mAuNPs to enhance the analytical signal of SPR immunosensors. For instance, a highly sensitive mAuNPs-based SPR immunosensor for the detection of Mycobacterium tuberculosis antigen CFP-10 protein was developed by Zou et al. A sandwich immunoassay was constructed by immobilizing capture anti-CFP-10 antibodies (Ab1) on the surface of the SPR sensor. After immunoreaction of the immobilized Ab1 and CFP-10 protein, mAuNPs functionalized with anti-CFP-10 detection antibodies were used to amplify the SPR signal and increased it 30 times at a LOD of 0.1 ng/mL. The analytical signal of the designed SPR immunosensor depends on the concentration of CFP-10 in the range 0.1–100 ng/mL. Liang et al. used mAuNPs to develop an SPR immunosensor for AFP detection. Amplification of the analytical signal by the sandwich detection format allowed AFP detection in the concentration range 1.0–200.0 ng/mL with a LOD of 0.65 ng/mL.

CD5, also known as lymphocyte antigen T1, Leu-1, and Ly-1, is a 67 kDa single chain transmembrane glycoprotein expressed by most T-cells, a subset of immunoglobulin M secreting B-cells known as B-1a cells, regulatory B-cells, or lymphoma cells, predominant in chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma. Several studies have shown that CD5 expression is a potentially prognostic factor of poor outcome in patients with diffuse large B-cell lymphoma. CD5 is present in ~80% of T-cell acute lymphoblastic leukemia and T-cell lymphoma and is considered one of the important biomarkers of malignant T-cells. However, to our knowledge, no SPR-based immunosensor for the quantification of CD5 has been developed. CD5 levels in biological fluids are very low, so it is necessary to develop an immunosensor with a very high sensitivity.

In this work, we provide our findings of an antibody-functionalized magnetoplasmonic nanoparticles-based SPR immunosensor signal amplification strategy for ultrasensitive quantification of the CD5 biomarker. Capture antibodies against human CD5 (anti-CD5A) were immobilized on the gold surface of the SPR sensor disk coated with an 11-mercaptoundecanoic acid (11-MUA) self-assembled monolayer (SAM). The primary amine groups of the anti-CD5A interacted with the carboxyl groups of 11-MUA previously activated with a mixture of N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The gold surface of mAuNPs was modified with 11-MUA SAMs, and detection antibodies against human CD5 (anti-CD5B) were covalently immobilized using the same EDC/NHS coupling chemistry. mAuNPs and anti-CD5B conjugates (mAuNPs–anti-CD5B) were separated from the colloidal suspension by an external magnetic field. Following immunoreaction of immobilized anti-CD5B and CD5, mAuNPs–anti-CD5B conjugates were used to amplify the SPR signal using an indirect sandwich immunoassay format. The proposed signal amplification strategy allowed us to achieve very good sensitivity and to determine femtomolar CD5 concentrations. Furthermore, the ability of the SPR immunosensor to quantify CD5 was tested by analyzing human blood serum with artificially added CD5 and appears to be suitable for analysis of biological samples.

2. EXPERIMENTAL SECTION

2.1. Materials and Reagents. Recombinant human CD5 protein (carrier free, predicted molecular mass 39.9 kDa, >95% purity by SDS-PAGE under reducing conditions and visualized by silver stain), anti-CD5A (monoclonal mouse IgG2A clone #205919, protein A or G purified from hybridoma culture supernatant), and anti-CD5B (monoclonal mouse IgG2B clone #205910, protein A or G purified from hybridoma culture supernatant) were purchased from R&D Systems (Abingdon, United Kingdom). Sodium dodecyl sulfate (SDS, ACS reagent, ≥99.0% purity, CAS Number: 151-21-3), sodium acetate trihydrate (NaAc, ACS reagent, ≥99.5% purity, CAS Number: 67-56-1), sodium dodecyl sulfate (SDS, ACS reagent, ≥99.5% purity, CAS Number: 151-21-3), 4-(2-hydroxyethyl)-1-pipera zineethanesulfonic acid (HEPES, ACS reagent, ≥98.0% purity, CAS Number: 6066-82-6), EDC (N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The gold surface of mAuNPs was modified with 11-MUA SAMs, and detection antibodies against human CD5 (anti-CD5B) were covalently immobilized using the same EDC/NHS coupling chemistry. mAuNPs and anti-CD5B conjugates (mAuNPs–anti-CD5B) were separated from the colloidal suspension by an external magnetic field. Following immunoreaction of immobilized anti-CD5B and CD5, mAuNPs–anti-CD5B conjugates were used to amplify the SPR signal using an indirect sandwich immunoassay format. The proposed signal amplification strategy allowed us to achieve very good sensitivity and to determine femtomolar CD5 concentrations. Furthermore, the ability of the SPR immunosensor to quantify CD5 was tested by analyzing human blood serum with artificially added CD5 and appears to be suitable for analysis of biological samples.
(HClO4, ACS reagent, 70% purity, CAS Number: 7601-90-3), and iron(II) sulfate heptahydrate (FeSO4·7H2O, ACS reagent, ≥99.0% purity, CAS Number: 7782-63-0) were obtained from Sigma-Aldrich (Steinheim, Germany). Ethanol absolute (≥99.8% purity, CAS Number: 64-17-5) was acquired from Honeywell (North Carolina, USA), refractive index (n = 1.518) matching fluid was acquired from Cargille Laboratories (Cedar Grove, New Jersey, USA), hydrogen tetrachloroaurate trihydrate (HAuCl4·3H2O, ACS reagent, ≥99.9% purity, CAS Number: 72988-77-8) was acquired from Alfa Aesar (Karlsruhe, Germany), sodium hydroxide (NaOH, pellets, Pharmurp, Ph Eur, BP, NF, CAS Number: 1310-73-2) was acquired from Scharlach S.L. (Sentmenat, Spain), and hydroxylamine hydrochloride (98% purity, CAS Number: 5470-11-1) was acquired from Lach-Ner (Neratovice, Czech Republic). Hexadecyltrimethylammonium bromide (CTAB, ≥99%, for biochemistry, CAS Number: 57-09-0), acetic acid (100%, Ph. Eur., extra pure, CAS Number: 64-17-5), n-sorbitol (≥98%, for biochemistry, CAS Number: 50-70-4), and phosphate buffered saline (PBS, for biochemistry and molecular biology) tablets were received from Carl Roth (Karlsruhe, Germany). Ethanolamine, hydrochloric acid (HCl, fuming, 37% purity, CAS Number: 7647-01-0), and sodium borohydride (NaBH4, for analysis, CAS Number: 1310-73-2) were acquired from J. T. Baker (Steinheim, Germany). Ethanol absolute (98% purity, CAS Number: 7782-63-0) were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Hydrochloric acid (HCl, fuming, 37% purity, CAS Number: 7647-01-0), and sodium hydroxide (NaOH, pellets, Pharmpur, ≥99%, for biochemistry, CAS Number: 1310-73-2) were acquired from J. T. Baker (Steinheim, Germany). Ethanol absolute (98% purity, CAS Number: 7782-63-0) were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Hydrochloric acid (HCl, fuming, 37% purity, CAS Number: 7647-01-0), and sodium hydroxide (NaOH, pellets, Pharmpur, ≥99%, for biochemistry, CAS Number: 1310-73-2) were acquired from J. T. Baker (Steinheim, Germany). Ethanol absolute (98% purity, CAS Number: 7782-63-0) were obtained from Sigma-Aldrich (St. Louis, Missouri, USA).

The determined average diameter of the synthesized mAuNPs was 47.6 ± 11.3 nm.

2.3. Preparation of mAuNPs—anti-CD52A. Prior to conjugation, the mAuNPs’ colloidal suspension was sonicated for 10 min in an ultrasonic bath. Then 1 mL of a colloidal suspension of mAuNPs was added to the test tube. The mAuNPs were collected with a magnet (collection time 10 min), and the supernatant was carefully poured off. The collected mAuNPs were then treated with 500 μL of UHQ water, and the resulting colloidal suspension was sonicated for 1 min. The mAuNPs were again collected with a magnet (collection time 10 min), and the supernatant was poured off. To successfully immobilize anti-CD52A, CTAB-free mAuNPs were treated in a concentrated solution of CD52A from the surface of the nanoparticles. For this purpose, the mAuNPs were treated with 500 μL of 30 mM NaBH4, and the resulting colloidal suspension was sonicated for 1 min and then stirred with a magnetic stirrer for 1 h. CTAB-free mAuNPs were then again collected with a magnet, treated with 500 μL of UHQ water, and sonicated for 1 min. Then solution of 500 μL of 1 mM 11-MUR in methanol was added to the collected mAuNPs. The colloidal suspension was sonicated for 1 min and then stirred for 2 h. After the formation of an 11-MUR SAM on the surface of the mAuNPs, the 11-MUR SAM modified particles were again collected with a magnet and treated with 500 μL of 10 mM PBS, pH 7.4, and the colloidal suspension was sonicated for 1 min. After collecting 11-MUR SAM modified mAuNPs with a magnet and pouring off supernatant, the carboxyl groups of the 11-MUA SAM were activated with a mixture of 200 μL of 0.4 mM EDC and 200 μL of 0.1 M NHS for 15 min after colloidal solution sonication for 1 min. Finally, after collection of the activated mAuNPs with a magnet, pouring off the supernatant, and washing the particles with 500 μL of 10 mM PBS, pH 7.4, with subsequent collection with a magnet, 500 μL of 133.33 nM anti-CD52A solution in PBS, pH 7.4, was added and the resulting colloidal suspension was stirred for 2 h. Then the mAuNPs—anti-CD52A conjugates were collected with a magnet, the supernatant with unbound antibodies was poured off, and the mAuNPs—anti-CD52A conjugates were washed with 500 μL of 10 mM PBS, pH 7.4, with subsequent collection with a magnet. Then, the mAuNPs—anti-CD52A conjugates were diluted to 500 μL in 10 mM PBS, pH 7.4, and the resulting colloidal suspension was stirred for 15 min and stored at +4 °C.

2.4. SPR Sensor Disk Surface Preparation and Immobilization of anti-CD52A. The surface of the new gold-coated SPR sensor disk (SD AU, XanTec Bioanalytics GmbH, Muenster, Germany) was cleaned by incubation in methanol for 30 min and hexane for 2 min and finally washed with UHQ water. The sensor disk was then immersed in a 1 mM solution of 11-MUA in methanol and kept there for 24 h at room temperature. The 11-MUA SAM modified sensor disk (Au/11-MUA) was washed with methanol and UHQ water, dried in an ambient environment, and placed on a hemicylinder mounted on a slider via a refractive index matching fluid. The slider was installed in a double channel SPR-analyzer Autolab Esprit (Metrohm Autolab BV, Utrecht, The Netherlands), and a cuvette (surface area of 7.9 mm² in one channel) was placed. The Au/11-MUA surface stabilization/rehydration was carried out by incubation for approximately 30 min at 2 min intervals in 10 mM NaAc coupling buffer, pH 4.5, and 10 mM glycine/HCl regeneration solution, pH 2.0, until a stable baseline was obtained. Anti-CD52A antibodies were immobilized in both channels of the SPR cuvette. The Au/11-MUA surface was first treated with coupling buffer for 200 s. A 1:1 mixture of 0.4 M EDC and 0.1 M NHS in water was then used to activate the 11-MUA carboxyl groups. The duration of activation was 600 s. After activation, the EDC/NHS mixture was removed by rinsing the cuvette with coupling buffer, and the resulting surface with active NHS esters was exposed to 500 nM anti-CD52A in coupling buffer for 1800 s. This results in robust amide bond formation between the primarily amine groups of anti-CD52A and the carboxyl groups of 11-MUA (Au/anti-CD52A). After washing the cuvette with coupling buffer and removing unbound anti-CD52A from the cuvette, the deactivation of the remaining activated carboxyl groups was carried out using 1 M ethanolamine solution, pH 8.5, for 600 s. Finally, Au/anti-CD52A was incubated in 10 mM PBS running buffer, pH 7.4, and regeneration solution at 2 min intervals for approximately 30 min until a stable baseline was obtained.

2.5. Anti-CD52A/CD5 Interaction and Regeneration of the Au/anti-CD52A. After reaching a stable baseline in 10 mM PBS running buffer, pH 7.4, for 200 s, a CDS solution in running buffer was injected into one channel of the SPR cuvette (measurement channel). The other channel was used as the reference (reference channel). Running buffer without CDS was injected into the reference channel for the negative control. The affinity interaction between the coated anti-CD52A and the carboxyl groups of 11-MUA was monitored, and the baseline was restored by exposure of Au/anti-CD52A in 10 mM PBS running buffer, pH 7.4, and, if necessary, a solution with a different concentration of CD5 was analyzed. The difference between the measurement and the reference channels was used to evaluate the anti-CD52A/CDS interaction.

2.6. Signal Amplification Using mAuNPs—anti-CD52A. An indirect sandwich immunoassay format was used for signal amplification. After the formation of the anti-CD52A/CDS immune complex on a sensor surface (Au/anti-CD52A/CDS), its interaction with detection anti-CD52A antibodies conjugated to mAuNPs was investigated. After reaching a stable baseline (200 s), Au/anti-CD52A was incubated in CDS solution in running buffer in the measurement channel of the cuvette for 600 s, followed by washing with running buffer for 100 s. The colloidal suspension of mAuNPs—anti-CD52A in 10 mM PBS, pH 7.4, was then injected into the measurement channel, and the interaction between Au/anti-CD52A/CDS and the conjugates was registered for 600 s, followed by dissociation in a running buffer for 100 s. Au/anti-CD52A/CDS was regenerated with a 10 mM glycine/HCl regeneration solution, pH 2.0, for 300 s, and the baseline was restored by running buffer treatment. The reference channel was filled with the pure running buffer. The difference between the measurement and reference channels was used to evaluate the interaction.
2.7. Analysis of CD5 Spiked Human Blood Serum Samples. CD5 spiked human blood serum was used to simulate the analysis of real samples. The 10 times with 10 mM PBS, pH 7.4, diluted serum was used in this experiment. Samples were prepared by using the addition technique according to which the diluted serum was spiked with a known concentration of CD5: 1.04, 26.02, and 63.53 pM. The principle of CD5 detection was the same as described above for standard CD5 samples. First, Au/anti-CD5 2A was incubated with sera spiked with CD5, and then, a colloidal suspension of mAuNPs−anti-CD5 2B in 10 mM PBS, pH 7.4, was injected into the SPR cuvette measurement channel. Pure running buffer was injected into the reference channel. The difference between the measurement and reference channels was used to evaluate the interaction. The measurement was repeated three times for a serum sample with the same CD5 concentration.

2.8. Calculations. The surface concentration of immobilized capture anti-CD5 2A antibodies was calculated from a linear relationship between the SPR angle shift and the amount of bound biomolecules. The change in the 120 m° SPR angle corresponds to a change in the biomolecules’ surface concentration of 1 ng/mm2. The regeneration efficiency was evaluated based on the baseline SPR signal recorded before Au/anti-CD5 2A and CD5 interaction (θSPR before interaction) and the baseline SPR signal recorded when the Au/anti-CD5 2A/CD5 was treated with regeneration solution and finally 10 mM PBS, pH 7.4 (θSPR after interaction):

\[
\text{Regeneration efficiency} = \frac{\theta_{\text{SPR after interaction}}}{\theta_{\text{SPR before interaction}}} \times 100\%
\]

The SPR signal generated interacting anti-CD5 2A and CD5 or anti-CD5 2A/CD5 immune complex and mAuNPs−anti-CD5 2B under steady-state conditions (equilibrium angle) was calculated by approximating the results obtained during the association phase according to the hyperbolic function \( y = ax/(b + x) \), where the parameter \( a \) is the equilibrium angle, m°.

The LOD was estimated as the concentration of CD5 that gives an SPR signal equal to 3 standard deviations of the baseline noise. Meanwhile, the limit of quantification (LOQ) was estimated as the concentration of CD5 that gives the SPR signal equal to 10 standard deviations of the baseline noise. All experimental results were represented as a mean value of three independent measurements with the error bars.

3. RESULTS AND DISCUSSION

In this study, a signal enhancement strategy for the SPR immunosensor was developed for the quantification of the CD5 biomarker. To achieve this, capture anti-CD5 2A antibodies were immobilized on the gold surface of the SPR sensor disk modified with an 11-MUA SAM via their primary amino groups by activating the carboxyl groups of 11-MUA with a mixture of EDC and NHS. The gold surface of the mAuNPs was modified with an 11-MUA SAM, and detection anti-CD5 2B antibodies were covalently immobilized using the same EDC/NHS coupling chemistry. mAuNPs−anti-CD5 2B conjugates were collected from the colloidal suspension by an external magnetic field. Following the immunoreaction of immobilized anti-CD5 2A and CD5 in a solution, mAuNPs−anti-CD5 2B conjugates were used to amplify the SPR signal in an indirect sandwich immunoassay format. Since the SPR signal depends on the change in the refractive index of the medium near a metal surface, which is proportional to the molecular weight of the bound analyte, the binding of larger molecules results in a higher signal. Therefore, due to the high mass of mAuNPs−anti-CD5 2B, the signal of the immunosensor increased significantly and became suitable for the detection of significantly lower concentrations of CD5. The main principles of mAuNPs−anti-CD5 2B preparation, immobilization of capture anti-CD5 2A antibodies, detection of CD5 by a direct immunoassay format, and amplification of the SPR signal using mAuNPs−anti-CD5 2B in an indirect sandwich immunoassay format are shown in Figure 1.

In order to determine the optimal conditions for CD5 detection, the concentration of the capture anti-CD5 2A antibody solution used for immobilization and the duration of immobilization were first optimized. A carbodiimide−succinimide immobilization method based on the activation of carboxyl functional groups using a mixture of EDC and NHS in water was chosen for immobilization. Activation of the carboxyl groups available on the SPR sensor surface with this mixture yields highly reactive N-hydroxysuccinimide esters that react with the primary amino functional groups of the proteins, forming a strong amide bond between the protein and the surface. Antibodies are immobilized in a random manner due to their asymmetric structure, and some of their antigen-binding sites might be inaccessible to the analyte. Despite this, the EDC/NHS coupling technique is very simple and easy to perform, does not require additional antibody modification, and is therefore frequently used in the development of SPR
immunosensors. Solutions of 200.0, 300.0, and 500.0 nM anti-
CD52A in 10 mM NaAc coupling buffer, pH 4.5, were tested to
optimize the amount of anti-CD52A used for immobilization.
To increase the ligand coupling yield during immobilization, it
is recommended to increase its concentration near the surface
of the SPR sensor due to electrostatic interaction. For this, the
surface must have a negative charge and the amino group of
the antibodies a positive charge. The pI of human IgG2 subclass antibodies is 7.4 ± 0.6.\(^{24}\) The pK\(_a\) of a surface-
attached acid through the SAM formation is defined as the pH
value of the solution that is in contact with the modified
surface when half of the SAM acid functional groups are
ionized\(^{25}\) and depends on many factors, including the nature of
the surface-attached acid, as well as the composition and ionic
strength of the solution. The pK\(_a\) of an 11-MUA SAM deposited
on a gold film in 1.0 M NaClO\(_4\) solution was determined to be 4.4 ± 0.2. The pK\(_a\) value of the 11-MUA SAM,
determined by potentiostatic infrared titration, was 4.3,\(^{26}\) while the pK\(_a\) value 3.3 ± 0.1 was detected for 11-MUA
at an AuNPs/aqueous interface.\(^{27}\) Therefore, taking this into
account, when the pH value of the buffer solution is 4.5, anti-
CD52A has a positive charge, while the remaining nonactivated
11-MUR carboxyl functional groups have a negative charge.
Electrostatic interaction increases the concentration of anti-
CD52A near the sensor surface, resulting in an increase in the
surface concentration of the immobilized antibody, which
determines the magnitude of the SPR signal generated by the
antibody–analyte interaction and, therefore, the sensitivity of
the assay.

As shown in Figure 2A, the surface concentration of
immobilized anti-CD52A increased with increasing concen-

![Figure 2](https://doi.org/10.1021/acsami.2c02936)

**Figure 2.** Dependence of the anti-CD52A surface concentration on (A) the concentration of these antibodies in the solution and (C) the immobilization duration. Impact of the anti-CD52A surface concentration on the SPR signal (B). Experimental conditions: (A and B) 1800 s duration of immobilization; (B) 50.14 nM CDS; (C) 500.0 nM anti-CD52A.

tration of its solution: 2.04 ± 0.11 (200.0 nM), 2.73 ± 0.19
(300.0 nM), and 3.81 ± 0.21 (500.0 nM). The calculated SPR
signal induced by the interaction of immobilized anti-CD52A
with the same amount of CDS (50.14 nM) also increased with
increasing concentration of antibody solution and was 23.82 ±
2.12, 30.36 ± 2.30, and 33.29 ± 2.60 m\(^2\) at 200.0, 300.0, and
500.0 nM, respectively (Figure 2B). As can be seen from the
results, the use of 500 nM anti-CD52A results in a surface
concentration 1.40 times higher than 300 nM, but the SPR
signal induced by the anti-CD52A and CDS interaction
increases only slightly. Based on the results obtained, it can
be stated that a further increase in the anti-CD52A
centration will not cause a significant increase in the SPR
signal during the interaction. Thus, the optimal anti-CD52A
centration can be considered to be 500.0 nM.

The surface concentration depends not only on the
concentration of the antibody solution used for immobilization
but also on the duration of immobilization. Figure 2C shows
that the surface concentration of anti-CD52A increases with
increasing duration of immobilization. The surface concen-
tration of anti-CD52A was found to be 2.76 ± 0.19, 3.73 ±
0.28, and 3.82 ± 0.29 ng/mm\(^2\) at an immobilization duration
of 1200, 1800, and 2400 s, respectively. Comparing the
obtained results, it can be seen that the increase of the surface
concentration after 1800 s becomes insignificant, and the
duration of the whole immobilization process is significantly
extended. Therefore, 1800 s can be considered as the optimal
duration of immobilization.

Regeneration of the surface of the SPR immunosensor
allows it to be used for multiple analyses. The goal of
regeneration is to disrupt the antibody–antigen immune
complex without reducing the activity of the immobilized
antibody or affecting its structure. During regeneration,
molecules adsorbed on the surface due to nonspecific sorption
can also be removed from the immunosensor surface. If the
antibody–antigen complex is not disrupted, then the antibody
immobilized on the surface of the immunosensor can no
longer interact with the analyte, and a lower SPR signal can be
recorded at the same concentration. Therefore, to avoid errors
in the analysis, it is very important to select a suitable solution
for regeneration, which would ideally have a recovery efficiency
of 100% or as high as possible. Regeneration solutions having
acidic or basic pH as well as surfactants were used to
regenerate the Au/anti-CD52A/CDS surface. After association
of immobilized anti-CD52A with 50.14 nM CDS in 10 mM
PBS, pH 7.4, and subsequent dissociation of the anti-CD52A/
CDS immune complex, the surface of the immunosensor was
exposed to the regeneration solution for 300 s, and the
regeneration efficiency was evaluated from the recorded
sensogram.

The experimental results presented in Figure 3A show that
the solutions with the best regeneration efficiency were 10 mM
glycine/HCl, pH 2.0 (99.77 ± 1.15%), and 10 mM glycine/
HCl, pH 1.0 (99.88 ± 1.18%). As can be seen, the
regeneration efficiencies of these solutions were very similar,
so it was decided to use a less drastic pH solution to avoid
possible inactivation of immobilized anti-CD52A during
repeated regeneration. By examining the dependence of the
regeneration efficiency of 10 mM glycine/HCl, pH 2.0, on the
duration of regeneration (Figure 3B), it was observed that the
regeneration efficiency improved with increasing regeneration
duration and was 93.52 ± 2.40, 99.77 ± 1.15, 99.87 ± 2.00,
and 99.93 ± 2.64% for the regeneration durations of 200, 300,
400, and 500 s, respectively. It is obvious that the regeneration
efficiency practically does not improve after 300 s; therefore,
due to the possible inactivation of anti-CD52A during repeated
regeneration, the optimal duration of Au/anti-CD52A/CDS
surface regeneration was assumed to be 300 s.

The sensitivity of the optimized SPR immunosensor was
examined by analyzing solutions of different concentrations
of CDS in 10 mM PBS, pH 7.4. The surface of Au/anti-CD52A
was exposed to 10 mM PBS, pH 7.4, until a stable SPR angle
was established, and then, CDS solution was injected into the
with diAu/anti-CD52A was almost completely regenerated. This 202.12 nM. The experimental results show that the surface of
was treated with 10 mM glycine/HCl, pH 2.0, regeneration solution, and then 10 mM PBS, pH 7.4, in order to restore the baseline.

Dependence of the Au/anti-CD52A/CD5 surface regeneration efficiency on (A) the regeneration solution and (B) the duration of regeneration. Experimental conditions: (A) 1800 s duration of 500.0 nM anti-CD52A immobilization, 50.14 nM CD5, 300 s duration of regeneration; (B) 10 mM glycine/HCl, pH 2.0, regeneration solution.

SPR cuvette measurement channel. The formation of the anti-CD52A/CD5 immune complex caused an increase in the SPR angle (Figure 4A). PBS buffer was injected at the end of the
association phase, resulting in partial dissociation of the resulting immune complex. Finally, the Au/anti-CD52A/CD5 was treated with 10 mM glycine/HCl, pH 2.0, regeneration solution, and then 10 mM PBS, pH 7.4, in order to restore the baseline.

Figure 4A shows the SPR sensograms recorded for solutions with different CD5 concentrations using (A) a direct immunoassay format and (B) a calibration curve. Experimental conditions: 1800 s duration of 500.0 nM anti-CD52A immobilization, 300 s duration of regeneration, 10 mM glycine/HCl, pH 2.0, regeneration solution.

It can also be seen that the shift in the SPR angle was dependent on the concentration of CD5 in the sample. For each sensogram, the SPR signal under steady-state conditions (equilibrium angle) was calculated and plotted against the CD5 concentration (Figure 4B). A linear relationship was observed with $R^2 = 0.9998$ between CD5 concentrations in the range of concentrations studied. The LOD was estimated to be 1.04 nM and the LOQ 3.47 nM at a signal-to-noise ratio of 3 and 10, respectively.

One of the main goals in the development of SPR immunosensors, as well as other biosensors, is the ability to apply them to the testing of biological samples, such as urine, saliva, blood plasma, or serum. Furthermore, matrix effects caused by species of high molecular weight present in any complex biological samples hinder the application of SPR immunosensors. Therefore, such samples should normally be diluted in buffer before analysis. Because the concentrations of various analytes in biological samples are very low, the immunosensor must be able to detect nanomolar or even femtomolar concentrations in order to be suitable for the analysis of these samples. The levels of soluble CD5 circulating in human serum are relatively very low, ranging from 1 to 24 ng/mL (0.015–0.36 nM). In the serum of healthy subjects, CD5 is detected at concentrations with a median of 1.75 ng/mL. Elevated serum CD5 levels have been reported in patients with certain autoimmune diseases, such as Sjogren’s syndrome, rheumatoid arthritis or atopic dermatitis, as well as some non-autoimmune diseases, such as septic syndrome, bladder cancer, non-small cell lung cancer, and others. Therefore, the immunosensor signal that is recorded during the direct anti-CD52A and CD5 interaction is inefficient to detect such low CD5 levels in biological samples. Thus, an indirect sandwich immunosensor format was used to increase the sensitivity and reduce the detection limit. Since the SPR signal of the immunosensor depends on the change in the refractive index of the medium near the metal surface, thus, the signal was significantly increased due to the high mass of mAuNPs−anti-CD52B. In addition, the SPR signal was increased due to the electromagnetic enhancement in the evanescent field at the SPR sensor surface caused by the localized surface plasmons excited in the nanoparticles. Following anti-CD52A and CD5 immunoreaction, a colloidal suspension of mAuNPs−anti-CD52B in 10 mM PBS, pH 7.4, was injected into the measuring channel of the SPR cuvette. The interaction of Au/anti-CD52A/CD5 with conjugates was observed for 600 s, followed by dissociation in PBS buffer for 100 s and regeneration using 10 mM glycine/HCl, pH 2.0, for 300 s. Finally, the baseline was restored by treatment with PBS buffer. Sensograms recorded during the Au/anti-CD52A/CD5 and mAuNPs−anti-CD52B interaction are shown in Figure 5A.

An increase in SPR signal was registered with increasing CD5 concentration, indicating an effective interaction between Au/anti-CD52A/CD5 and mAuNPs−anti-CD52B. A linear relationship between the CD5 concentration and the calculated equilibrium angle ($R^2 = 0.9989$) was observed over the entire range of concentrations studied from 0.05 to 99.26 pM (Figure 5B). The LOD was estimated to be 8.31 fM and the LOQ 27.70 fM at a signal-to-noise ratio of 3 and 10, respectively.
A comparison of the analytical characteristics of the developed SPR immunosensor signal amplification strategy with some reported SPR immunosensors based on signal amplification with high-mass antibody-functionalized nanoparticles is presented in Table 1. As can be seen, the proposed strategy achieves similar or even significantly better analytical characteristics.

The sensitivity and specificity of the developed indirect sandwich format SPR immunosensor were assessed by testing human serum samples. A series of samples were prepared by spiking 10-fold diluted serum with CD5 at different concentrations. Each serum sample was tested in triplicate. Sensograms were recorded, and the equilibrium angles and their average values for each CD5 concentration were calculated. The CD5 concentration in the serum sample was determined by a calibration curve made by analyzing solutions of known CD5 concentration in the range 0.05–99.26 pM and by the derived linear equation. As shown in Table 2, the recovery rates were in an acceptable 10% range, indicating that the immunosensor had good accuracy in the serum matrix. The fact that a higher concentration of CD5 was obtained than spiked can be explained by the very low amount of CD5 in the serum itself, as well as by the non-specific sorption of serum matrix components that produces a non-specific response. Both cause an additional signal independent of the amount of CD5 spiked.

### 4. CONCLUSIONS

This study proposed a signal amplification strategy for the SPR immunosensor based on the use of antibody-functionalized magnetoplasmonic nanoparticles and an indirect sandwich immunoassay format. Due to the high mass and the electromagnetic enhancement in the evanescent field at the SPR sensor surface caused by the localized surface plasmons excited in the nanoparticles, the binding of the mAuNPs–anti-CD52B to the anti-CD52A/CD5 immune complex caused a drastic increase in SPR signal, thus ensuring significant amplification of CD5 detection. Compared to the direct detection format with the LOD of 1.04 nM and the LOQ of 3.47 nM, the use of mAuNPs–anti-CD52B allowed reduction of the LOD and LOQ to 8.31 and 27.70 nM, respectively. The immunosensor also showed satisfactory performance in human blood serum (recovery of 1.04 pM of CD5 was 109.62%). These results indicate that the proposed signal amplification strategy has advantageous properties and offers promising potential to significantly increase the sensitivity of SPR immunosensors. This is extremely important for clinical purposes when ultralow concentrations need to be determined. Due to these advantages, it is also likely that the proposed

### Table 1. Comparison of Analytical Characteristics of Some SPR Immunosensors Based on Signal Amplification with High-Mass Antibody-Functionalized Nanoparticles

| High-mass conjugates | Analyte     | LOD (pM) | Linear range       | Reference |
|----------------------|-------------|----------|--------------------|-----------|
| mAuNPs–anti-CD52B    | CD5         | 8.31     | 1.0–200.0 ng/mL    | This work |
| QDs–anti-AFP         | AFP         | 0.1      |                    | 7         |
| QDs–anti-CEA         | CEA         | 0.1      |                    |           |
| QDs–anti-CYFRA 21–1  | CYFRA 21–1  | 0.1      |                    |           |
| AuNP[n]–anti-CEAbiot | CEA         | 0.1      |                    | 36        |
| mAuNPs–anti-AFP      | AFP         | 0.65     | 0.1–100.0 ng/mL    | 14        |
| mAuNPs–anti-CFP-10   | CFP-10      | 0.1      | 0.5–40.0 ng/mL     | 13        |
| AuNP[n]–anti-CEAbiot | CEA         | 88.8     |                    | 8         |
| AuNPs–anti-cTnT      | cTnT        | 0.5      |                    | 37        |
| MWCNTs–anti-TauP     | TauP        | 125      | 125–1000 pM        | 38        |
| AuNP[n]              | ErbB2       | 180      | 0.23–55 ng/mL      | 9         |
| MBsstr               | BNP         | 25       |                    | 39        |
| MBsstr               | SEB         | 100–1000 |                    | 40        |
| MBs–anti-βhCG        | βhCG        | 0.45     |                    | 41        |

*QDs, quantum dots; AFP, α-fetoprotein; anti-AFP, antibodies against AFP; CEA, carcinoembryonic antigen; anti-CEA, antibodies against CEA; CYFRA 21–1, cytokeratin fragment 21–1; anti-CYFRA 21–1, antibodies against CYFRA 21–1; AuNP[n], streptavidin modified AuNPs; anti-CEAbiot, biotinylated antibodies against CEA; CFP-10, culture filtrate protein; anti-CFP-10, antibodies against CFP-10; cTnT, cardiac troponin T; anti-cTnT, antibodies against cTnT; MWCNTs, multiwalled carbon nanotubes; TauP, Tau protein; anti-TauP, antibodies against TauP; ErbB2, human epidermal growth factor receptor 2; MBsstr, streptavidin modified magnetic beads; BNP, brain natriuretic peptide; SEB, Staphylococcal enterotoxin B; βhCG, β human chorionic gonadotropin; anti-βhCG, antibodies against βhCG.*
signal amplification strategy based on antibody-functionalized magnetoplasmmonic nanoparticles would be useful in the development of other mass-sensitive immunoassays, such as quartz crystal microbalance immunoassays or others.

**AUTHOR INFORMATION**

**Corresponding Authors**

Asta Kausaite-Minkstiene — Nanotechnas – Center of Nanotechnology and Materials Science, Institute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, LT-03225 Vilnius, Lithuania; Department of Immunology, State Research Institute Centre for Innovative Medicine, LT-08406 Vilnius, Lithuania; Email: asta.kausaite@chf.vu.lt

Almira Ramanaviciene — Nanotechnas – Center of Nanotechnology and Materials Science, Institute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, LT-03225 Vilnius, Lithuania; Department of Immunology, State Research Institute Centre for Innovative Medicine, LT-08406 Vilnius, Lithuania; Email: almira.ramanaviciene@chf.vu.lt

**Author**

Anton Popov — Nanotechnas – Center of Nanotechnology and Materials Science, Institute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, LT-03225 Vilnius, Lithuania; Department of Immunology, State Research Institute Centre for Innovative Medicine, LT-08406 Vilnius, Lithuania

Complete contact information is available at: https://pubs.acs.org/10.1021/acsami.2c02936

**Funding**

This project has received funding from the European Social Fund (project no. 09.3.3-LMT-K-712-19-0170) under a grant agreement with the Research Council of Lithuania (LMTLT).

**Notes**

The authors declare no competing financial interest.

**REFERENCES**

1. Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71 (3), 209–249.
2. Whitaker, K. Earlier Diagnosis: The Importance of Cancer Symptoms. Lancet Oncol. 2020, 21 (1), 6–8.
3. Ramanaviciene, A.; Kausaite-Minkstiene, A.; Popov, A.; Brasunas, B.; Ramanavicius, A. Design of Immunosensors for Rapid and Sensitive Detection of Biomarkers. In The Detection of Biomarkers: Past, Present and the Future Prospects; Ozkan, S. A., Bakirhan, N. K., Mollarasouli, F. B. T.-T. D. of B., Eds.; Academic Press, 2022; Chapter 12, pp 303–333. DOI: 10.1016/B978-0-12-822859-3.00009-2.
4. Kausaite-Minkstiene, A.; Ramanavicius, A.; Ruksnaitė, J.; Ramanaviciene, A. A Surface Plasmon Resonance Immunosensor for Human Growth Hormone Based on Fragmented Antibodies. Anal. Methods 2013, 5 (18), 4757–4763.
5. Mohsini, S.; Moghadam, T. T.; Dabirmansesh, B.; Jabbari, S.; Khajeh, K. Development of a Label-Free SPR Sensor for Detection of Matrixmetalloproteinase-9 by Antibody Immobilization on Carboxymethyldeextran Chip. Biosens. Bioelectron. 2016, 81, 510–516.
6. Jena, S. C.; Shrivastava, S.; Saxena, S.; Kumar, N.; Maiti, S. K.; Mishra, B. P.; Singh, R. K. Surface Plasmon Resonance Immunosensor for Label-Free Detection of BIRC5 Biomarker in Spontaneously Occurring Canine Mammary Tumours. Sci. Reports 2019 91 2019, 9 (1), 1–12.
7. Wang, H.; Wang, X.; Wang, J.; Fu, W.; Yao, C. A SPR Biosensor Based on Signal Amplification Using Antibody-QD Conjugates for Quantitative Determination of Multiple Tumor Markers. Sci. Reports 2016 61 2016, 6 (1), 1–9.
8. Ermini, M. L.; Song, X. C.; Sprunger, T.; Homola, J. Peptide Functionalization of Gold Nanoparticles for the Detection of Carcinoembryonic Antigen in Blood Plasma via SPR-Based Biosensor. Front. Chem. 2019, 7 (Feb). DOI: 10.3389/FCHEM.2019.00040.
9. Eletxegierra, U.; Martinez-Pediguero, J.; Barderas, R.; Pingarrón, J. M.; Campuzano, S.; Merino, S. Surface Plasmon Resonance Immunosensor for ErbB2 Breast Cancer Biomarker Determination in Human Serum and Raw Cancer Cell Lysates. Anal. Chim. Acta 2015, 905, 156–162.
10. Krishnan, S.; Mani, V.; Wasalathanthri, D.; Kumar, C. V.; Rusling, J. F. Attomolar Detection of a Cancer Biomarker Protein in Serum by Surface Plasmon Resonance Using Superparamagnetic Particle Labels. Angew. Chem., Int. Ed. Engl. 2011, 50 (5), 1175–1178.
11. Popov, A.; Stirke, A.; Bakute, N.; Brasunas, B.; Ramanavicius, A.; Ramanaviciene, A. Efficiency of Granulocyte Colony-Stimulating Factor Immobilized on Magnetic Microparticles on Proliferation of NFS-60 Cells. Colloids Surfaces A Physicochem. Eng. Asp. 2019, 578, 123580.
12. Fathi, F.; Rashidi, M. R.; Omid, Y. Ultra-Sensitive Detection by Metal Nanoparticles-Mediated Enhanced SPR Biosensors. Talanta 2019, 192, 118–127.
13. Zhou, F.; Wang, X.; Qi, F.; Koh, K.; Lee, J.; Zhou, H.; Chen, H. Mageto-Plamonic Nanoparticles Enhanced Surface Plasmon Resonance TB Sensor Based on Recombinant Gold Binding Antibody. Sensors Actuators B Chem. 2017, 250, 356–363.
14. Liang, R. P.; Yao, G. H.; Fan, L. X.; Qiu, J. D. Magnetic Fe3O4@Au Composite-Enhanced Surface Plasmon Resonance for Ultrasensitive Detection of Magnetic Nanoparticle-Enriched α-Fetoprotein. Anal. Chem. Acta 2012, 737, 22–28.
15. Ahmad, D.; Ahmad, T. A.; Ahmad, S.; Tipu, H. N.; Wiqar, M. A. CD5-Positive Acute Lymphoblastic Leukemia. J. Coll. Physicians Surg. Pak. 2008, 18 (5), 310–311.
16. Lee, J. H.; Noh, J.; Noh, G.; Choi, W. S.; Lee, S. S. IL-10 Is Predominantly Produced by CD19(LOW)CD5(POSITIVE) T Cells: Characterisation of CD19(LOW)CD5(POSITIVE) Regulatory B Cell Subpopulation: Characterisation of CD19 (High) and CD19(Low) CD5(Positive) Lymphoblastic Leukaemia. J. Coll. Physicians Surg. Pak. 2008, 18 (5), 310–311.
17. Xu-Monette, Z. Y.; Tu, M.; Jabbar, K. J.; Cao, X.; Tzankov, A.; Visco, C.; Cai, Q.; Montes-Moreno, S.; An, Y.; Dybkaer, K.; Chiu, A.; Orazi, A.; Xu, Y.; Bhagat, G.; Richards, K. L.; Hsi, E. D.; Choi, W. W.; Van Krieken, J. H.; Huh, J.; Ponzoni, M.; Ferreri, A. J. M.; Zhao, X.; Moller, M. B.; Farnen, J. P.; Winter, J. N.; Piris, M. A.; Miranda, R. N.; Medeiros, L. J.; Young, K. H. Clinical and Biological Significance of de Novo CD5+ Diffuse Large B-Cell Lymphoma in Western Countries. Oncotarget 2015, 6 (8), 5615–5633.
18. Kausaite-Minkstiene, A.; Kausaite-Minkstiene, A.; Popov, A.; Brasunas, B.; Ramanavicius, A. Design of Immunosensors for Rapid and Sensitive Detection of Biomarkers. In The Detection of Biomarkers: Past, Present and the Future Prospects; Ozkan, S. A., Bakirhan, N. K., Mollarasouli, F. B. T.-T. D. of B., Eds.; Academic Press, 2022; Chapter 12, pp 303–333. DOI: 10.1016/B978-0-12-822859-3.00009-2.
(21) Xu, Y.; Liu, Q.; Zhong, M.; Wang, Z.; Chen, Z.; Zhang, Y.; Xing, H.; Tian, Z.; Tang, K.; Liao, X.; Rao, Q.; Wang, M.; Wang, J. 2B4 Costimulatory Domain Enhancing Cytotoxic Ability of Anti-CDS Chimeric Antigen Receptor Engineered Natural Killer Cells against T Cell Malignancies. J. Hematol. Oncol. 2019, 12 (1), 1–13.

(22) Ramanaviciene, A.; Popov, A.; Baluinaite, E.; Brasinius, B.; Kausiute-Minkstimiene, A.; Tamer, U.; Kirdaite, G.; Bernotiene, E.; Mobasher, A. Magneto-Imunoassay for the Detection and Quantification of Human Growth Hormone. Biosens. 2022, Vol. 12, Page 65 2022 (2), 65.

(23) He, J.; Unser, S.; Bruzas, I.; Cary, R. J.; Shi, Z.; Mehra, R.; Aron, K.; Sagle, L. The Facile Removal of CTAB from the Surface of Gold Nanorods. Colloids Interfaces 2018, 163, 140–145.

(24) Hamilton, R. G. Human LγG Subclass Measurements in the Clinical Laboratory. Clin. Chem. 1987, 33 (10), 1707.

(25) Smalley, J. F.; Chalfant, K.; Feldberg, S. W.; Nahir, T. M.; Bowden, E. F. An Indirect Laser-Induced Temperature Jump Determination of the Surface PKa of 11-Mercaptoundecanoic Acid Monolayers Self-Assembled on Gold. J. Phys. Chem. B 1999, 103 (10), 1676–1685.

(26) Luque, A. M.; Cuesta, A.; Calvente, J. J.; Andreu, R. Potentiostatic Infrared Titration of 11-Mercaptoundecanoic Acid Monolayers. Electrochem. commun. 2014, 45, 13–16.

(27) Ma, J.; Mandal, S.; Bronsther, C.; Gao, Z.; Eisenhal, K. B. Second Harmonic Study of Acid-Base Equilibrium at Gold Nanoparticle/Aqueous Interface. Chem. Phys. Lett. 2017, 683, 166–171.

(28) Treviño, J.; Calle, A.; Rodríguez-Frade, J. M.; Mellado, M.; Lechuga, L. M. Determination of Human Growth Hormone in Human Serum Samples by Surface Plasmon Resonance Immunoassay. Talanta 2009, 78 (3), 1011–1016.

(29) Calvo, J.; Places, L.; Espinosa, G.; Padilla, O.; Vilà, J. M.; Villamor, N.; Ingelmo, M.; Gallart, T.; Vives, J.; Font, J.; Lozano, F. Identification of a Natural Soluble Form of Human CDS. Tissue Antigens 1999, 54 (2), 128–137.

(30) Ramos-Casals, M.; Font, J.; García-Carrasco, M.; Calvo, J.; Places, L.; Padilla, O.; Cervera, R.; Bowen, M. A.; Lozano, F.; Ingelmo, M. High Circulating Levels of Soluble Scavenger Receptors (SCDS and SCD6) in Patients with Primary Sjögren’s Syndrome. Rheumatology (Oxford). 2001, 40 (9), 1056–1059.

(31) Jamin, C.; Magadur, G.; Lamour, A.; Mackenzie, L.; Lydyard, P.; Katsikis, P.; Youinou, P. Cell-Free CDS in Patients with Rheumatic Diseases. Immunol. Lett. 1992, 31 (1), 79–83.

(32) Noh, G.; Lozano, F. Intravenous Immune Globulin Effects on Serum-soluble CDS Levels in Atopic Dermatitis. Clin. Exp. Allergy 2001, 31, DOI: 10.1046/j.1365-2222.2001.01124.x

(33) Abar, J.; Martínez-Floresena, M.; Castro, P.; Carrasco, E.; Escoda-Ferran, C.; Fernández, S.; Butjosa, M.; Hernández, C.; Rinaudo, M.; Lozano, F.; Nicolás, J. M. Pattern of Soluble CDS and CD6 Lymphocyte Receptors in Critically III Patients with Septic Syndromes. J. Crit. Care 2015, 30 (5), 914–919.

(34) Roudfashani, Z.; Jazayeri, M. H.; Mahmoudi, A. R.; Nedaenina, R.; Safari, E.; Jazayeri, A. Evaluation of the Frequency of CD5+ B Cells as Natural Immunoglobulin M Producers and Circulating Soluble CDS in Patients with Bladder Cancer. Mol. Biol. Rep. 2019, 46 (6), 6405–6411.

(35) Moreno-Manuel, A.; Jantus-Lewintre, E.; Simões, I.; Aranda, F.; Calabuig-Fariñas, S.; Carreras, E.; Záliga, S.; Saenger, Y.; Rosell, R.; Camps, C.; Lozano, F.; Sirera, R. CDS and CD6 as Immunoregulatory Biomarkers in Non-Small Cell Lung Cancer. Transl. Lung Cancer Res. 2020, 9 (4), 1074–1083.

(36) Springer, T.; Homola, J. Biofunctionalized Gold Nanoparticles for SPR-Biosensor-Based Detection of CEA in Blood Plasma. Anal. Bioanal. Chem. 2012, 404 (10), 2869–2875.

(37) Pawula, M.; Altintas, Z.; Thotthil, I. E. SPR Detection of Cardiac Troponin T for Acute Myocardial Infarction. Talanta 2016, 146, 823–830.

(38) Lisi, S.; Scarano, S.; Fedeli, S.; Pascale, E.; Cicchi, S.; Ravelet, C.; Peyrin, E.; Minunni, M. Toward Sensitive Immuno-Based Detection of Tau Protein by Surface Plasmon Resonance Coupled to Carbon Nanostructures as Signal Amplifiers. Biosens. Bioelectron. 2017, 93, 289–292.

(39) Teramura, Y.; Arima, Y.; Iwata, H. Surface Plasmon Resonance-Based Highly Sensitive Immunosensing for Brain Natriuretic Peptide Using Nanobeads for Signal Amplification. Anal. Biochem. 2006, 357 (2), 208–215.

(40) Soelberg, S. D.; Stevens, R. C.; Limaye, A. P.; Furlong, C. E. Surface Plasmon Resonance Detection Using Antibody-Linked Magnetic Nanoparticles for Analyte Capture, Purification, Concentration, and Signal Amplification. Anal. Chem. 2009, 81 (6), 2357–2365.

(41) Wang, Y.; Dostalek, J.; Knoll, W. Magnetic Nanoparticle-Enhanced Biosensor Based on Grating-Coupled Surface Plasmon Resonance. Anal. Chem. 2011, 83 (16), 6202–6207.